Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Accutar Biotechnology, Cranbury, New Jersey recently announced via BioSpace that dosing has begun with the first patient enrolled in the Phase 1 trial of AC0676 a chimeric degrader molecule…
The American Society of Clinical Oncology (ASCO) held its Annual Meeting from June 2-6, 2023. During the meeting, a variety of stakeholders discussed clinical practices, guidelines, trends, and research related…
John Hornsby Sr., a native of Kentucky, suffered for six months with what he thought was a hernia. John was wrong. He had incurable Non-Hodgkin’s follicular lymphoma, and surgery…
The U.S. Food and Drug Administration (FDA) has recently granted approval to tisagenlecleucel, which is marketed under the name Kymriah, for adult patients with relapsed or refractory (R/R) follicular lymphoma…
According to a story from Targeted Oncology, the company Genmab has recently announced that the US Food and Drug Administration (FDA) has granted Orphan Drug designation to its investigational therapy…
According to a story from AJMC, the drug developer Incyte has made the decision to withdraw its New Drug Application (NDA) for its investigational therapy parsaclisib. This therapy was submitted…
Biotechnology company Genmab A/S recently shared that its investigational therapy epcoritamab (DuoBody-CD3xCD20), being developed with AbbVie, was granted Orphan Drug designation from the FDA. The therapy is designed for those…
A recent study has uncovered that a CAR-T therapy called Kymriah could lead to improved results for follicular lymphoma patients. Specifically, it was found to be both effective and safe…
In a news release from late January 2022, biopharmaceutical company CASI Pharmaceuticals, Inc. ("CASI") shared that the Company's partner, BioInvent International AB ("BioInvent") recently earned an Orphan Drug designation from…
Incyte has withdrawn its New Drug Application (NDA) for parsaclisib, which is an investigational treatment for various types of lymphoma, including relapsed/refractory mantle cell lymphoma (MCL), follicular lymphoma, and marginal…
Currently, there are a number of treatment options for patients with follicular lymphoma. But for patients whose condition has relapsed despite prior treatments, there are very limited therapeutic options. After…
According to a recent article, the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition displayed the advances that have been made in the management of follicular lymphoma. Follicular…
Grant and award programs can be crucial in spurring therapeutic discovery and development. According to News Medical, this is what the Follicular Lymphoma Foundation (FLF) aims to do with its…
According to a recent article, Connie Lee Batlevi, MD, PhD, who is a medical oncologist, recently shared her experiences and knowledge pertaining to the treatment of follicular lymphoma. Follicular Lymphoma…
The FDA will review parsaclisib as a treatment for Non-Hodgkin lymphoma (NHL) after accepting Incyte's New Drug Application (NDA). Specifically, the NDA was submitted for the treatment of relapsed or…
Chimeric antigen receptor (CAR) T-cell therapy has proven to be a successful therapy for a number of conditions; however, we do not see the same success in follicular lymphoma and…
Dr. Javier Munoz, the director of the Mayo Clinic's Lymphoma program in Phoenix, has recently conducted an interview with Kristie Kahl, the Vice President of content for the Cancer Network.…
According to a video from OncLive, Dr. John P. Leonard from Weill Cornell Medicine discussed the role of PI3K inhibitors in the treatment of follicular lymphoma, a rare cancer. While…
In a video conversation recorded for Cancer Network, Kristie L. Kahl and Javier L. Munoz, MD, MS, FACP discussed treatment for relapsing/remitting follicular lymphoma and the importance of the sequencing…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Normally, B lymphocytes ("B cells") are a type of white blood cell that plays a role in immune function. In healthy individuals, B cells create antibodies to fight infections and…
During the European Hematology Association (EHA)'s 26th Annual Meeting, taking place virtually, biopharmaceutical company Kite (part of Gilead) shared longer-term follow-up data on Yescarta (axicabtagene ciloleucel) for patients with relapsed…
According to a recent article in the Seattle Cancer Care Alliance, the FDA’s recent approval of Axi-cel (Yescarta) will improve the chances of survival for relapsed or refractory follicular lymphoma.…
A recent study examined three different follicular lymphoma (FL) patients to try to better understand how the disease presents differently for different individuals. Ultimately, this study has reiterated the importance…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
